Kaseb Hatem, Mukkamalla Shiva Kumar R., Rajasurya Venkat
Cleveland Clinic
Presbyterian Healthcare Services
Anaplastic lymphoma kinase positive (ALK+) anaplastic large cell lymphoma (ALCL) is a peripheral T-cell lymphoma (PTCL) that consists of characteristic large pleomorphic lymphoid cells with abundant cytoplasm and horseshoe-shaped nuclei, strongly positive for CD30 immunohistochemical staining. ALK+ ALCL has associated recurrent t(2;5) fusion translocation involving the ALK gene and nucleophosmin (NPM1) gene. Ki-1 lymphoma is the old terminology that refers to the CD30 (previously designated as Ki-1 antigen) positive lymphomas, exhibiting a morphology resembling malignant histiocytes, but having overlapping immunohistochemical features of classic Hodgkin's lymphoma. The 2016 revised World Health Organization (WHO) lymphoma classification includes four distinct entities under ALCL: systemic ALK-positive ALCL (ALK+ ALCL), systemic ALK-negativeALCL (ALK- ALCL), primary cutaneous ALCL (pC ALCL), and the provisional entity breast implant-associated ALCL (BI-ALCL).
间变性淋巴瘤激酶阳性(ALK+)间变性大细胞淋巴瘤(ALCL)是一种外周T细胞淋巴瘤(PTCL),由具有丰富细胞质和马蹄形核的特征性大的多形性淋巴细胞组成,CD30免疫组化染色呈强阳性。ALK+ ALCL伴有涉及ALK基因和核磷蛋白(NPM1)基因的复发性t(2;5)融合易位。Ki-1淋巴瘤是旧术语,指CD30(以前称为Ki-1抗原)阳性淋巴瘤,形态学上类似于恶性组织细胞,但具有与经典霍奇金淋巴瘤重叠的免疫组化特征。2016年修订的世界卫生组织(WHO)淋巴瘤分类在ALCL下包括四个不同实体:系统性ALK阳性ALCL(ALK+ ALCL)、系统性ALK阴性ALCL(ALK- ALCL)、原发性皮肤ALCL(pC ALCL)以及临时实体乳房植入物相关ALCL(BI-ALCL)。